Case Study: Moexipril Hydrochloride: A Prodrug of Moexiprilat
Moexiprilat is an orally active, nonsulfhydryl, long-acting dipeptide angiotensin-converting enzyme (ACE) inhibitor used to lower blood pressure (Stimpel et al., 1995; Brogden and Wiseman, 1998; Chrysant and Chrysant, 2003). Moexipril hydrochloride shows improved bioavailability compared to moexiprilat, most likely because esterification reduces the charge of the molecule and the pKa of its amine group (pKa Moexprilat = 7.7; pKa Moexipril = 5.4). Based on the comparable oral bioavailabilities of various esters of enalapril with different lipophilicities, it appears that lipophilicity is not the only factor that enhances oral bioavailability (Wyvratt and Patchett, 1985).
KeywordsSevere Essential Hypertension Male Human Volunteer Show Maximum Stability Isoquinolinecarboxylic Acid Additional Medical Benefit
Unable to display preview. Download preview PDF.
- Hoefle ML, and Klutchko S. Substituted Acyl Derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acids. US Patent 4,344,949, August 17, 1982Google Scholar
- Klutchko S, Blankley CJ, Fleming RW, Hinkley JM, Werner AE, Nordin I, Holmes A, Hoefle ML, Cohen DM, Essenburg AD, and Kaplan HR. Synthesis of Novel Angiotensin Converting Enzyme Inhibitor Quinapril and Related Compounds. A Divergence of Structure-Activity Relationships for Non-Sulfhydryl and Sulfhydryl Types. J Med Chem 1986; 29:1953–1961PubMedCrossRefGoogle Scholar